{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/immunizations-pneumococcal/management/children-diagnosed-at-increased-risk-aged-2-5-years/","result":{"pageContext":{"chapter":{"id":"c9787edf-835f-54d9-9b86-b7c8695307ef","slug":"children-diagnosed-at-increased-risk-aged-2-5-years","fullItemName":"Scenario: Children diagnosed at increased risk aged 2-5 years","depth":2,"htmlHeader":"<!-- begin field 75fb60c6-e7a1-47e4-a8b6-852c403a9aca --><h2>Scenario: Children diagnosed at increased risk aged 2-5 years</h2><!-- end field 75fb60c6-e7a1-47e4-a8b6-852c403a9aca -->","summary":"Covers the management of children aged 2–5 years who are diagnosed at high risk of pneumococcal disease.","htmlStringContent":"<!-- begin item 00affc5f-6148-4e41-8fb8-4ddad627de64 --><!-- begin field 619e2791-263e-416d-a06d-acd900ae19e4 --><p>From age 24 months to 5 years.</p><!-- end field 619e2791-263e-416d-a06d-acd900ae19e4 --><!-- end item 00affc5f-6148-4e41-8fb8-4ddad627de64 -->","topic":{"id":"af89c4a4-b7c5-5032-9cab-157c542f213b","topicId":"667146c4-e374-494f-a050-b8976e5e7056","topicName":"Immunizations - pneumococcal","slug":"immunizations-pneumococcal","lastRevised":"Last revised in January 2021","chapters":[{"id":"c2a8d969-5d35-5185-b666-883786b066c5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9db009c1-59ed-5d79-9446-33e54e1676c7","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"cf4adec7-88ef-5a0f-b072-53bd3049b260","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5459dd7c-ac40-5828-8bec-840fa7fca764","slug":"changes","fullItemName":"Changes"},{"id":"197178ce-11cd-52df-883c-419e06744dd4","slug":"update","fullItemName":"Update"}]},{"id":"95a44f6b-2987-5086-8656-ef21fcbbc28b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"006db835-5d01-5085-a6e1-ee57f7ca41c8","slug":"goals","fullItemName":"Goals"},{"id":"29af8dc8-13e9-56c4-a041-b00bbf320b1e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e7b32647-3434-5f3f-b8be-51203e3ebfee","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ebc71bdc-4766-5946-bb16-121b9da544f3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3daf6a12-bce0-53d4-a318-05cc49aab107","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4dce4bc5-1119-5c5d-9422-d275fc956a4e","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"002fbb60-3041-597d-9d3d-fc3a17068591","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"37c59838-49d0-51d5-8203-1eae848738c2","slug":"definition-of-pneumococcal-disease","fullItemName":"Definition of pneumococcal disease"},{"id":"aba9a3c5-f0f7-5e65-b369-1947461d0158","slug":"prevalence-of-pneumococcal-disease","fullItemName":"Prevalence of pneumococcal disease"},{"id":"9da9e662-ccc4-5bc4-bae8-eb3f0ec80b19","slug":"risk-factors-for-pneumococcal-disease","fullItemName":"Risk Factors for pneumococcal disease"},{"id":"492f20c5-5e03-51dc-9ccb-1994f3db1c35","slug":"pneumococcal-immunization","fullItemName":"Pneumococcal immunization"}]},{"id":"e183f01f-d538-542b-bc16-6f849966d1d2","fullItemName":"Management","slug":"management","subChapters":[{"id":"b036915e-0e64-5fea-a247-9777822304b3","slug":"routine-vaccination-of-infants-adults-over-65-years-of-age","fullItemName":"Scenario: Routine vaccination of infants, and adults over 65 years of age"},{"id":"8f83b7e0-d764-5bca-a03b-e549e24f402a","slug":"children-diagnosed-at-increased-risk-under-2-years-of-age","fullItemName":"Scenario: Children diagnosed at increased risk under 2 years of age"},{"id":"c9787edf-835f-54d9-9b86-b7c8695307ef","slug":"children-diagnosed-at-increased-risk-aged-2-5-years","fullItemName":"Scenario: Children diagnosed at increased risk aged 2-5 years"},{"id":"7f443a07-5081-5296-b56e-8b82550f8c52","slug":"children-over-5-years-of-age-adults-diagnosed-at-increased-risk","fullItemName":"Scenario: Children over 5 years of age and adults diagnosed at increased risk"}]},{"id":"f17e101b-7bea-59aa-9b9c-46924bbfdc2b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"871f5861-588e-57ef-9521-0a81e77d4583","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d0a50959-6448-5a18-8845-f75f5c40f388","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"92b33782-e97b-565d-b432-b19376ecedbc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5b1e27f9-71f0-5238-978b-5648b601e292","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2b6c5d09-7606-5742-89c4-19fa3b671fd7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"037af05f-e510-5862-b316-4676f7c3a61e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"04bd9328-ed11-5b9d-ba9a-06584ecd6f33","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e183f01f-d538-542b-bc16-6f849966d1d2","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"d4ed0cb0-1c4b-5827-82e1-a7d6c03520f0","slug":"children-aged-two-to-five-years","fullItemName":"Children aged two to five years","depth":3,"htmlHeader":"<!-- begin field 76d2ea86-d775-4edc-9542-acbb5a4f66c2 --><h3>How should I vaccinate children diagnosed at increased risk aged 2 to 5 years?</h3><!-- end field 76d2ea86-d775-4edc-9542-acbb5a4f66c2 -->","summary":null,"htmlStringContent":"<!-- begin item 189254a3-9ad4-4b32-b8a2-8c3f0dfe0d74 --><!-- begin field d525e0c1-d54f-443b-af9a-a300fac6acb6 --><ul><li><strong>People at increased risk of pneumococcal disease or complications include those with:</strong><ul><li>Asplenia or splenic dysfunction.</li><li>Chronic respiratory, heart, kidney, or liver disease.</li><li>Diabetes requiring insulin or oral hypoglycaemic drugs.</li><li>Immunosuppression due to a medical condition or treatment.</li><li>Cochlear implants.</li><li>Cerebrospinal fluid leaks (including leakage following trauma or major skull surgery).<ul><li>For more details, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/background-information/risk-factors-for-pneumococcal-disease/\">Risk factors</a>.</li></ul></li></ul></li><li><strong>Offer children aged 2 to 5 years who are diagnosed at increased risk of pneumococcal disease but without significant immunosuppression, </strong><strong>and who</strong> <strong>have completed the <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/management/routine-vaccination-of-infants-adults-over-65-years-of-age/#routine-infant-pneumococcal-vaccination\">routine immunization schedule</a></strong> a dose of pneumococcal polysaccharide vaccine (PPV23) (Pneumovax<sup>®</sup>) at least 2 months after the last dose of the 13-valent pneumococcal conjugate vaccine (PCV13) (Prevenar 13<sup>®</sup>).<ul><li>At-risk children in this group who are unvaccinated or partially vaccinated should receive a dose of PCV13, followed by a dose of PPV23 at least 2 months later.</li></ul></li><li><strong>If the child has asplenia, splenic dysfunction, or is immunocompromised </strong>(including bone marrow transplant recipients, children with acute and chronic leukaemia, or genetic disorders affecting the immune system):<ul><li>Offer one dose of PCV13 followed by PPV23 at least 2 months later if the child is fully vaccinated.</li><li>Offer two doses of PCV13 at least two months apart, followed by PPV23 at least 2 months later if the child is unvaccinated or partially vaccinated.</li></ul></li><li>At-risk children who are eligible for one or two doses of PCV13 but who have already received PPV23 should wait at least 6 months between PPV23 and PCV13 doses.</li><li>If there is no reliable immunization history, it should be assumed that the child has not been vaccinated.</li></ul><!-- end field d525e0c1-d54f-443b-af9a-a300fac6acb6 --><!-- end item 189254a3-9ad4-4b32-b8a2-8c3f0dfe0d74 -->","subChapters":[{"id":"e6eaf20a-3021-58c8-ac0e-f986355f8cb8","slug":"basis-for-recommendation-db5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b8fa81fe-b2c3-4818-9ec9-d12bd15a8960 --><h4>Basis for recommendation</h4><!-- end field b8fa81fe-b2c3-4818-9ec9-d12bd15a8960 -->","summary":null,"htmlStringContent":"<!-- begin item db5dd10f-6b99-4ae3-bf53-fd26089cf450 --><!-- begin field dea919be-e099-4bf0-a16a-554230088941 --><p>The recommendations on pneumococcal immunization are based government policy as discussed in Chapter 25 of <em>Immunisation against infectious disease</em> (the 'Green Book'), published by the Department of Health [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013a</a>].</p><!-- end field dea919be-e099-4bf0-a16a-554230088941 --><!-- end item db5dd10f-6b99-4ae3-bf53-fd26089cf450 -->","subChapters":[]}]},{"id":"2b57b9ca-8135-5069-a71c-f3d6b46825b7","slug":"how-to-administer-the-vaccine","fullItemName":"How to administer the vaccine","depth":3,"htmlHeader":"<!-- begin field cf38f81a-d250-4a0b-8f6d-04a5a14697fc --><h3>How to administer the vaccine</h3><!-- end field cf38f81a-d250-4a0b-8f6d-04a5a14697fc -->","summary":null,"htmlStringContent":"<!-- begin item 8f82d929-dd05-4c98-bc5e-c4de9a788431 --><!-- begin field d9c2d787-c0a6-4f41-830a-e123b217b5e7 --><ul><li><strong>Obtain written or verbal consent at the time of vaccination from a person with parental responsibility.</strong></li><li><strong>Ensure that:</strong> <ul><li>There are no contraindications to the vaccine.<ul><li>The only absolute contraindication to pneumococcal vaccination is a confirmed previous anaphylactic reaction to the vaccine or one of its components.</li></ul></li><li>The parent or carer has been fully informed about the vaccine and the vaccination procedure.</li><li>Possible adverse reactions have been discussed and the parent, or carer is aware of how to manage them. </li><li>The vaccine is correct, has been stored appropriately, and has not expired. </li><li>The vaccination site has been washed with soap and water if it is visibly dirty.</li></ul></li><li><strong>For children who are acutely unwell (for example with a fever or acute infection), postpone pneumococcal immunization until they have fully recovered.</strong> Minor illness without fever or systemic upset is not a valid reason to postpone immunization. </li><li><strong>Pneumococcal vaccines are usually given by intramuscular (IM) injection, into the upper arm in children. </strong>However, if the child has a bleeding disorder, the vaccine should be given by deep subcutaneous (SC) injection to reduce the risk of bleeding. <ul><li>Use a 25mm 23-gauge (blue) or 25-gauge (orange) needle for IM administration in children.</li></ul></li><li><strong>Pneumococcal vaccines can be given at the same time as other vaccines. </strong>If an additional vaccine is required on the same day, use separate limbs if possible, or inject at sites at least 2.5 cm apart. </li><li><strong>Record the date of administration, vaccine and product name, batch number, expiry date, dose administered, and site of administration for each vaccine.</strong> </li><li><strong>Observe the child after vaccination to detect immediate adverse reactions.</strong> Ensure any bleeding has stopped and check for any symptoms of anaphylaxis before they leave.<ul><li>Anaphylaxis is extremely rare, and usually becomes apparent within minutes. By the time the site has been checked for bleeding and documentation has been completed, most reactions will have become apparent. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li></ul></li></ul><!-- end field d9c2d787-c0a6-4f41-830a-e123b217b5e7 --><!-- end item 8f82d929-dd05-4c98-bc5e-c4de9a788431 -->","subChapters":[{"id":"2cbb7d68-a9ff-50a9-b546-a2d7ba5f663f","slug":"basis-for-recommendation-fb2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 8b16d1c5-4027-4622-8da5-78785696c337 --><h4>Basis for recommendation</h4><!-- end field 8b16d1c5-4027-4622-8da5-78785696c337 -->","summary":null,"htmlStringContent":"<!-- begin item fb2af057-175b-428a-8b72-c69302006d42 --><!-- begin field 6def4b60-47b8-4c8f-bdd5-7714b6342ff0 --><p>These recommendations are based on chapters in <em>Immunisation against infectious disease</em> (the 'Green Book') published by Public Health England (PHE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013c</a>], [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013d</a>], [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013b</a>], and what CKS considers to be good clinical practice.</p><h5>Obtaining consent</h5><ul><li>Consent for immunizations does not legally have to be in writing, but must be given voluntarily by a fully informed person who is able to make and communicate their decision. For children not competent to give or withhold consent, a person with parental responsibility can provide this [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013c</a>].</li></ul><h5>Site of administration</h5><ul><li>The site of administration depends on the child's age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013d</a>]:<ul><li>Over the age of 1 year, vaccines are routinely given into the deltoid muscle as it is convenient, providing easy access, and it reduces the risk of localized reactions, which are common when vaccines are given subcutaneously.</li><li>The gluteal muscle should be avoided. The needle may not penetrate through adipose tissue into the muscle, and this may cause a poor immunological response to the vaccine. In addition, there is a risk of damage to underlying structures such as the sciatic nerve.</li></ul></li></ul><!-- end field 6def4b60-47b8-4c8f-bdd5-7714b6342ff0 --><!-- end item fb2af057-175b-428a-8b72-c69302006d42 -->","subChapters":[]}]},{"id":"9639bc93-f41e-5e00-b3b6-4d365b70d496","slug":"advice-for-parents","fullItemName":"Advice for parents","depth":3,"htmlHeader":"<!-- begin field d7f377ea-ca6c-43d8-b2f2-f8b8352e9604 --><h3>Advice for parents</h3><!-- end field d7f377ea-ca6c-43d8-b2f2-f8b8352e9604 -->","summary":null,"htmlStringContent":"<!-- begin item a152f22b-5525-4b79-9f05-ffb5bbd63b6f --><!-- begin field 56b96a3b-a585-4ffa-8d5b-69c089b5a20e --><ul><li><strong>Explain the benefits of vaccination,</strong> in particular that it helps prevent a major cause of meningitis in young children. <ul><li>Information about vaccinations (including the UK childhood immunization schedule, vaccine safety, risks and benefits, and individual vaccines) is available on the NHS website, at <a data-hyperlink-id=\"ed4ab7c8-7e0b-4dc9-88a1-a98e0033a61d\" href=\"https://www.nhs.uk/conditions/\">www.nhs.uk</a>.</li></ul></li><li><strong>Reassure that vaccinations are safe, and serious adverse effects are very rare.</strong> Pain, swelling, and reddening at the site of injection are most common and systemic adverse effects, should they occur, are usually limited to mild fever.</li><li><strong>Advise parents or carers not to routinely give paracetamol or ibuprofen to prevent fever around the time of vaccination.</strong> However if pain or fever is problematic after the child has been vaccinated, then paracetamol or ibuprofen may be used. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a>.</li><li><strong>Offer parents or carers written information,</strong> such as the Public Health England patient information leaflets <a data-hyperlink-id=\"6c68e451-676e-4e47-a6a4-a98e0033a66b\" href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/448789/8584-what-to-expect-after-vaccination-2015-2P-A5-02-web.pdf\" style=\"background-color: rgb(255, 255, 255);\">What to expect after vaccinations</a>.</li></ul><!-- end field 56b96a3b-a585-4ffa-8d5b-69c089b5a20e --><!-- end item a152f22b-5525-4b79-9f05-ffb5bbd63b6f -->","subChapters":[{"id":"51c636d1-422b-5eb2-8f40-b4ea7f27839e","slug":"basis-for-recommendation-83c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a6449cd9-e8cb-4a87-ba62-7ccada9dcbe8 --><h4>Basis for recommendation</h4><!-- end field a6449cd9-e8cb-4a87-ba62-7ccada9dcbe8 -->","summary":null,"htmlStringContent":"<!-- begin item 83c5d9ca-bd71-4d2f-a317-ed87641aa342 --><!-- begin field 867c289f-498c-472e-8a1d-afdf6113a242 --><p>The recommendations on advice to give about pneumococcal immunization are based on information in the chapter on vaccine safety and adverse effects following immunization in <em>Immunisation against infectious disease</em> (the 'Green Book') published by Public Health England (PHE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013b</a>], and are pragmatic, based on what CKS considers to be good clinical practice.</p><h5>Explaining the benefits of vaccination</h5><ul><li>Many parents find the process of having their children immunized distressing. Explaining the benefits of vaccination and giving reassurance about the limited nature of any adverse effects should be helpful.</li></ul><h5>Using paracetamol or ibuprofen</h5><ul><li>CKS found no controlled trials on the efficacy of paracetamol or ibuprofen in reducing pain or fever following vaccination. As paracetamol and ibuprofen have been shown to reduce fever and pain in conditions such as the common cold and influenza [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">Eccles, 2006</a>], it can be reasonably extrapolated that they may be effective in relieving these symptoms on an 'as required' basis after vaccination. </li><li>PHE recommends that paracetamol or ibuprofen should not be given to prevent fever in children who receive pneumococcal vaccinations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013b</a>]. It states that there is no evidence that paracetamol or ibuprofen prevent febrile convulsions and that there is some evidence that they may lower antibody responses to some vaccines when given around the time of vaccination [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">Prymula et al, 2009</a>].</li></ul><!-- end field 867c289f-498c-472e-8a1d-afdf6113a242 --><!-- end item 83c5d9ca-bd71-4d2f-a317-ed87641aa342 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}